Buscar
Mostrando ítems 1-6 de 6
Advances in hepatitis B therapeutics
(Therapeutic Advances in Infectious Disease, 2020-10)
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
Oral antivirals for the prevention and treatment of SARS-CoV-2 infection
(AIDS Reviews, 2022)
Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening
viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease
manifestations ...
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies
(Journal of Viral Hepatitis, 2022)
Chronic hepatitis C virus (HCV) infection is major cause of decompensated cirrhosis and liver cancer. The advent of curative new antiviral therapies since year 2015 has dramatically improved the prognosis of HCV patients. ...
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
(Hepatology International, 2022)
Background: Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, ...
Viral hepatitis in persons living with HIV in the post-COVID era
(AIDS reviews, 2023)
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
(Alimentary Pharmacology and Therapeutics, 2023)
Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...